Charles River Establishes a New Facility in Korea to Provide Endosafe Products and Services

12-Apr-2007

Charles River Laboratories announced the establishment of Charles River Endosafe Korea. Effective May 1, 2007, Endosafe®products will be sold and supported directly by the new, wholly owned Korean operation. The focus of Endosafe Korea's scientific staff will be to promote and ensure regulatory compliance, to expand sales of Endosafe products in Korea, and to provide enhanced and focused technical service and support for our Asian customers.

The new Korean facility will directly supply Endosafe products, ensuring customers rapid product availability and direct communication with the supplier. Customers will also receive technical support with response to questions provided by in-house experts.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board

Currently positioned only 5th, China is the fastest growing biotech market in the world

BGU researchers make scientific breakthrough in the fight against neurodegenerative diseases - BGN Technologies secures funding of over $1m. to develop patented treatment

Pivotal phase IIIa trials for Organon's novel oral contraceptive, NOMAC/E2, complete recruitment

Gene Logic Expands GeneExpress Product Line, Launches GeneExpress Women's Health DataSuite - New Product Enables Analysis of Distinctions in Female and Male/ Female Gene Expression

Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine - IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer

New findings about stem cells in the brain of patients with epilepsy

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product